3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
3
Ovarian Neoplasms
2
Neoplastic Syndromes, Hereditary
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Kidney Neoplasms
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Hematologic Neoplasms
1
Cytopenia
1
Congenital Bone Marrow Failure Syndromes
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Colorectal Neoplasms
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Bone Marrow Failure Disorders
1
Interventions
Bevacizumab
76
Fluorouracil
56
Cetuximab
47
Leucovorin
44
Oxaliplatin
43
pembrolizumab
35
Irinotecan
34
Folfox protocol
24
Capecitabine
24
HMPL-013
22
Specimen Handling
18
trifluridine tipiracil drug combination
16
Nivolumab
15
Blood Specimen Collection
15
Panitumumab
14
regorafenib
13
Magnetic Resonance Spectroscopy
13
Trifluridine
12
Standard of Care
12
Gemcitabine
12
Biopsy
12
Cisplatin
11
sintilimab
10
Interviews as Topic
10
IFL protocol
10
Drug Therapy
10
Carboplatin
9
tislelizumab
8
Trastuzumab
8
Cyclophosphamide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colorectal Neoplasms
×
Genetic Counseling
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled